Advanced hormone-sensitive prostate cancer responds to androgen-deprivation therapy (ADT); however, therapeutic options for recurrent castration-resistant disease are limited. Because growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) are regulated in an autocrine fashion in prostate cancer, inhibition of GHRH-R represents a compelling approach to treatment. We investigated the effects of the latest series of improved, highly potent GHRH antagonists-MIA-602, MIA-606, and MIA-690-on the growth of androgen-dependent as well as castration-resistant prostate cancer (CRPC) cells in vitro and in vivo. GHRH-R and its splice variant, SV1, were present in 22Rv1, LNCaP, and VCaP human prostate cancer cell lines. Androgen-dependent LNCaP and VCaP cells expressed higher levels of GHRH-R protein compared with castration-resistant 22Rv1 cells; however, 22Rv1 expressed higher levels of SV1. In vitro, MIA-602 decreased cell proliferation of 22Rv1, LNCaP, and VCaP prostate cancer cell lines by 70%, 61%, and 20%, respectively (all P < 0.05), indicating direct effects of MIA-602. In vivo, MIA-602 was more effective than MIA-606 and MIA-690 and decreased 22Rv1 xenograft tumor volumes in mice by 63% after 3 wk (P < 0.05). No noticeable untoward effects or changes in body weight occurred. In vitro, the VCaP cell line was minimally inhibited by MIA-602, but in vivo, this line showed a substantial reduction in growth of xenografts in response to MIA-602, indicating both direct and systemic inhibitory effects. MIA-602 also further inhibited VCaP xenografts when combined with ADT. This study demonstrates the preclinical efficacy of the GHRH antagonist MIA-602 for treatment of both androgen-dependent and CRPC.
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androgen-independent | G protein-coupled receptor | hypothalamic neurohormone | neuropeptide | targeted therapy P rostate carcinoma is the most common noncutaneous cancer in US males and represents the second-leading cause of their cancer-related deaths (1) . The mainstay treatment for advanced or metastatic prostate carcinoma is androgen-deprivation therapy (ADT) (2, 3) . Although initially ADT is beneficial and reduces tumor burden, tumors ultimately recur in a form termed hormoneinsensitive or castration-resistant prostate cancer (CRPC) (4) . There are few treatment options for CRPC, none of which is curative; thus, new approaches to treat or prevent CRPC or its progression are needed.
Growth hormone-releasing hormone (GHRH), a neuropeptide produced in the hypothalamus, regulates the secretion of growth hormone (GH) by the pituitary by binding to GHRH receptor (GHRH-R), a G protein-coupled receptor (5-7). Hypothalamic neurohormone GHRH and GHRH-R are not confined to the hypothalamic-pituitary axis, however, but are also produced by various extrahypothalamic sites. GHRH/GHRH-R modulates cell proliferation and apoptosis in many tissues, including prostate (8) (9) (10) (11) (12) .
In prostate cancer, GHRH antagonist JV-1-38 induces apoptosis in the LNCaP cell model through a calcium-dependent mechanism (11) . In models of CRPC, GHRH antagonist JMR-132 suppresses AKT and ERK signaling cascades, thereby decreasing cell proliferation and survival (13) . These results indicate that GHRH antagonists have pleiotropic antitumor mechanisms.
Most prostate cancer specimens express GHRH-R as well as its ligand GHRH, which function together in an autocrine fashion to stimulate proliferation (14) . In addition, a splice variant of GHRH-R, termed SV1, is expressed in many cancers, including prostate, ovarian, and pancreatic cancers (15, 16) . Unlike fulllength GHRH-R, SV1 displays ligand-independent activity in addition to ligand-dependent activity (17) . Numerous investigations have examined the effects of GHRH antagonists on metastasis, invasion, and tumor growth in various cancer types (13, (18) (19) (20) (21) (22) (23) (24) (25) (26) . Many of these published studies used early-stage GHRH antagonists that were later deemed unsuitable for clinical development owing to limited stability or low potency. In the present study, we investigated several of the latest series of highly potent GHRH antagonists with improved design and resistance to biodegradation represented by MIA-602, MIA-606, and MIA-690. The MIA series is based on an earlier antagonist, JMR-132, which contains several substitutions within the first 29 amino
Significance
Therapeutic options for recurrent castration-resistant prostate cancer (CRPC) are limited and more effective treatment regimens are needed. Antagonists of growth hormone-releasing hormone (GHRH) inhibit growth of experimental models of human cancer cells, including prostate cancer, by suppressing the actions of tumoral growth factors, particularly GHRH itself, which is an autocrine/paracrine growth factor in many tumors. Here we investigated the antitumor effects of the latest series of highly potent GHRH antagonists-MIA-602, MIA-606, and MIA-690-on androgen-dependent as well as CRPC lines expressing receptors for GHRH. MIA-602 inhibited in vivo growth of both androgen-dependent and CRPCs and decreased cell proliferation in vitro. This study provides evidence of the preclinical efficacy of GHRH antagonist MIA-602 in the treatment of human prostate cancer.
acids of GHRH and functions as an antagonist with increased potency and stability (12, 21) .
Inhibition of GHRH-R in prostate carcinoma has direct effects on cells that harbor GHRH-R, as well as indirect systemic effects through attenuation of the insulin-like growth factor (IGF)-1 signaling axis (27, 28) . GH secretion, promoted by GHRH, stimulates the production of IGF-1 in the liver. IGF-1 is a potent mitogen and survival factor for prostate cancer cell lines and tumors whose actions can be blocked by targeting IGF-1 receptors (IGF1Rs) (29) (30) (31) (32) . Decreased production of IGF-1 by inhibition of GHRH-R by GHRH antagonists occurs in vivo (33) . Notably, the IGF-1 signaling axis is dysregulated in various cancers, including prostate cancer (34) (35) (36) (37) .
Here we show that human prostate cancer cell lines 22Rv1, LNCaP, and VCaP express GHRH-R as well as its splice variant, SV1, and that proliferation of 22Rv1, LNCaP, and VCaP cells is directly inhibited by administration of the GHRH antagonist MIA-602 to varying degrees, with VCaP cells the least sensitive. GHRH-R inhibition also decreases 22Rv1 xenograft growth in vivo. Importantly, although we found that VCaP cells were the least sensitive to MIA-602 treatment in vitro, VCaP xenografts were significantly inhibited by MIA-602 in vivo, consistent with both direct and indirect systemic effects of MIA-602. These findings demonstrate the preclinical efficacy of MIA-602 for treating prostate cancer and warrant further investigation into the use and mechanisms of GHRH antagonists for this disease.
Results

Expression of GHRH-R and SV1 in Human Prostate Cancer Cell Models.
To assess the effects of GHRH antagonists on tumor inhibition, we used several prostate cancer cell lines that are representative of both androgen-dependent prostate cancer and CRPC. LNCaP is an androgen-dependent cell line that does not express functional phosphatase and tensin homolog (PTEN), the negative regulator of AKT (38) . LNCaP expresses mutant, but functional full-length androgen receptor (AR). VCaP cells express WT PTEN (39, 40) , amplified WT AR, and the TMRPSS:ERG fusion, which is found in ∼50% of clinical prostate cancer specimens (41) . 22Rv1 is a model of CRPC that expresses WT PTEN, full-length mutated AR, and constitutively active AR splice variants (42, 43) . The growth of 22Rv1 depends on the presence of these AR splice variants (44) (45) (46) .
We examined the expression of GHRH-R, its splice variant SV1, and the ligand GHRH in LNCaP, 22Rv1, and VCaP human prostate cancer cell lines. GHRH-R and SV1 were present in all three cell lines examined. LNCaP and VCaP cells expressed similar levels of GHRH-R and SV1, whereas 22Rv1 cells had higher levels of SV1 and lower levels of GHRH-R (Fig. 1A) . VCaP cells expressed the highest levels of mRNA for GHRH-R, SV1, and GHRH (Fig. 1B) .
Inhibition of Prostate Cancer Cell Proliferation by GHRH Antagonist
MIA-602. To determine whether MIA-602 affects cellular proliferation, we treated 22Rv1, LNCaP, and VCaP cells with this peptide antagonist of GHRH-R. MIA-602 inhibited cell proliferation of LNCaP and 22Rv1 by 70.4% and 60.7%, respectively (P < 0.05 for both) ( Fig. 2 A and B) . VCaP was also inhibited, but to a lesser degree, by 20.3% compared with vehicle (P < 0.05) (Fig. 2C) . No correlation between GHRH-R or SV1 expression levels and inhibition of cell proliferation was apparent. These data show that prostate cancer cells express GHRH-R and SV1 receptor and are directly inhibited, to varying degrees, by GHRH antagonist MIA-602.
Inhibition of Growth of 22Rv1 Xenografts by GHRH Antagonists. Although treatment with GHRH antagonist inhibited castrationresistant 22Rv1 in vitro, we felt that it was essential to evaluate whether this inhibition could be produced in a more clinically relevant systemic setting, the xenograft model. Mice bearing 22Rv1 xenografts (average volume of 76 mm 3 ) were treated with GHRH antagonist MIA-602, MIA-606, or MIA-690 or vehicle for 4 wk. Tumors in MIA-602-treated mice were 2.7-fold smaller than tumors in vehicle-treated mice (Fig. 3A) . Tumors in mice treated with MIA-606 and MIA-690 were 1.7-fold smaller than those in vehicle-treated mice ( Fig. 3 B and C) . Thus, MIA-602 was the most effective antagonist tested. There were no differences in mouse body weights among the treatment groups (Table S1 ).
After 4 wk of treatment, we measured GHRH-R and SV1 expression levels in xenografts. Although there was considerable variability, treatment with MIA-602, MIA-606, or MIA-690 did not significantly affect protein or transcript levels of GHRH-R or SV1 (Fig. 3 D and E) . In addition, none of the GHRH antagonists tested significantly affected transcript levels of GHRH peptide (Fig. 3E) . Thus, there was no down-regulation of transcription of genes encoding GHRH-R, SV1, or ligand.
Inhibition of Growth of VCaP Xenografts by MIA-602. We examined the effects of GHRH antagonists in another relevant prostate cancer model, VCaP cells, which exhibited less sensitivity to MIA-602 in vitro (Fig. 2C) . Because VCaP cells are androgendependent prostate cancer cells that progress to castration resistance in vivo (29, (47) (48) (49) , we were able to test the inhibition of GHRH-R alone and in combination with ADT (standard of care) by castration. Mice bearing VCaP xenografts (average tumor volume of 248 mm 3 ) were subjected to sham surgery or castration and then treated with MIA-602 or vehicle. Treatment with MIA-602 reduced tumor volume by 2.3-fold compared with vehicle in intact (sham) mice after 3 wk of treatment (Fig. 4A) . Mice that were castrated and treated with MIA-602 also exhibited a 2.3-fold decreased tumor volume (Fig.  4B) , indicating no additional effect from castration. Serum prostate-specific antigen (PSA), a clinically relevant biomarker, was decreased in mice that received castration combined with MIA-602 treatment compared with mice treated with sham surgery and vehicle (Fig. S1 ). After combination treatment of ADT and MIA-602, serum PSA levels were similar to those at initiation of treatment (Fig. S1 ).
There were no significant differences in mean mouse body weight among the treatment groups (Table S2 ). Tumor weights (Fig. 4C) showed a trend similar to that seen in measured tumor volumes. No intergroup differences in the mRNA levels of GHRH-R, SV1, or GHRH (Fig. 4D ) or in GHRH-R, SV1, or GHRH protein levels were apparent (Fig. 4E) .
Discussion
Splice variants of GHRH receptors, especially SV1, are present in the pituitary, as well as in most tumors (8, 28) . GHRH antagonists competitively block the binding of tumoral autocrine or paracrine GHRH to pituitary-type GHRH-Rs or GHRH-R splice variants on tumors; thus, both types of GHRH-R should be considered potential targets for anticancer therapy with GHRH antagonists (6, 17) . The levels of SV1 seem to increase over those of pituitary-type GHRH-R, with an elevated grade of malignancy, or in transition from precancerous lesions to carcinomas (18, 21-23, 50, 51) . Our work shows that GHRH-R and its splice variant SV1 are expressed in the three prostate cancer cell lines 22Rv1, VCaP, and LNCaP.
Proliferation of prostate cancer cells depends at least in part on GHRH-R signaling, as demonstrated by our finding that MIA-602 decreased proliferation of all cell lines tested. This effect likely was caused by both cell cycle effects and increased apoptosis, as described in previous studies with GHRH antagonists (11-13, 23); however, specific markers of cell cycle and apoptosis were not evaluated in this study. Expression levels of GHRH-R and SV1 varied among the cell lines tested, and no correlation between of GHRH-R or SV1 level and sensitivity to MIA-602 was apparent. These data show that prostate cancer cell lines can be directly inhibited by MIA-602, although to varying degrees, through the GHRH-Rs expressed on these tumors.
Treatment with MIA-602, MIA-606, or MIA-690 inhibited growth of 22Rv1 xenografts compared with controls. MIA-602 was the most effective antagonist of the three evaluated. No changes in body weight among the treatment groups compared with controls were observed during this in vivo study, further supporting the preclinical suitability of MIA-602. These data suggest that MIA-602 may provide an effective treatment for advanced CRPC, which is currently considered incurable, with only limited treatment options.
Despite abundant expression of GHRH-R and SV1, VCaP cells were found to be the least sensitive to MIA-602 in vitro. Interestingly, when tested in vivo, inhibition of VCaP xenografts by MIA-602 was more pronounced than that in vitro and similar to that of 22Rv1 xenografts. As observed for 22Rv1 xenografts, the protein levels of GHRH-R and SV1 remained unchanged after MIA-602 administration. These findings suggest that the GHRH antagonist MIA-602 has direct effects on cells, as well as effects produced indirectly through systemic mechanisms.
Inhibition of the IGF-1 signaling axis using antibody to IGF-1R decreases proliferation and increases apoptosis of prostate cancer cells both in vitro and in vivo (29, 32, (52) (53) (54) . Inhibition of the IGF-1 signaling axis alone or in conjunction with ADT for the treatment of prostate cancer has shown favorable results in preclinical and early clinical trials (29) (30) (31) . VCaP cells are particularly sensitive to IGF-1R inhibition both in vitro and in vivo, as demonstrated through administration of ganitumab, an antibody to IGF-1R that blocks IGF-1 and IGF-2 binding (29) . Thus, diminution of IGF-1 levels associated with the inhibition of the GHRH-R has the potential to both directly and indirectly inhibit prostate cancer cell proliferation.
It is possible that the increased sensitivity of VCaP xenografts to MIA-602 was related in part to the attenuation of IGF-1 signaling achieved through reduced GH levels and thus reduced production of IGF-1 in the liver. We did not measure the levels of IGF-1 or IGF-1 signaling in this study, however. Early antagonists of GHRH, such as MZ-4-71, lowered blood levels of IGF-1 by inhibiting GH release (6) . Nevertheless, after we changed our assay for activity of subsequent synthetic GHRH antagonists from the inhibition of GH release to suppression of ) qRT-PCR from tumor mRNA was performed to obtain relative mRNA levels of GHRH-R, SV1, and GHRH (n = 3 per group). Data are mean ± SEM relative to 22Rv1 cell line mRNA. The same control group is reflected in A-C. n = 7-10 per group for xenograft experiments. *P < 0.05; ***P < 0.001, two-tailed Student t test.
tumor growth in vivo, we obtained GHRH antagonists with greatly increased antitumor activity, but with reduced GH and IGF-1 inhibiting activity (6, 22) . Thus, the main effect of latest GHRH antagonists such as MIA-602 is likely to be exerted by the suppression of the action of tumoral GHRH through the inhibition of its binding to GHRH-Rs, which results in decreased cell cycle progression as well as increased apoptosis (6, 13, 21, 50) . The present findings suggest that MIA-602 may be a useful treatment for androgen-dependent prostate cancer, both as a single agent and in combination with ADT. This in vivo study describes favorable systemic effects of MIA-602 that also affect prostate cancer growth and progression and thereby augment its efficacy.
This investigation indicates preclinical efficacy of the GHRH antagonist MIA-602 and related analogs for the treatment of prostate cancer. Administration of MIA-602 inhibits models of both androgen-dependent prostate cancer and CRPC through direct cellular effects, as well as through possible indirect systemic mechanisms. In conclusion, our findings suggest that antagonists of GHRH of the MIA-602 class may have clinical benefits against prostate cancer, and further investigation of these agents is warranted.
Materials and Methods
Cell Culture. The human prostate cancer cell lines LNCaP and 22Rv1 were obtained from and authenticated by American Type Tissue Culture Collection. VCaP cells were provided by Dr. Kenneth Pienta, Johns Hopkins University School of Medicine, Baltimore, MD (47) . All cell lines were tested and deemed negative for mycoplasma contamination and were used within 6 mo of resuscitation. VCaP cells were maintained in DMEM-H (Gibco) supplemented with antimycotic/antibiotic agents (Gibco) and 10% FBS (Atlanta Biological) (48) . LNCaP and CWR-22Rv1 cells were maintained in RPMI medium (CellGro) supplemented with penicillin/streptomycin (Gibco), L-glutamine (Gibco), and 10% FBS (Atlanta Biological).
Drugs and Chemicals. GHRH antagonists were prepared in our laboratory by solid-phase synthesis using Boc chemistry and purified by reversed-phase HPLC as described previously (6, 22, 25 ]hGH-RH(1-29)NH2. Noncoded amino acids and acyl groups used in the peptides are abbreviated as follows: Abu, α-aminobutyric acid; Ada, 12-aminododecanoic acid; Agm, agmatine; Cpa, parachloro-phenylalanine; Fpa5, pentafluoro-phenylalanine; Har, homoarginine; Me-Ala, Nmethyl-alanine; Nle, norleucine; Orn, ornithine; PhAc, phenylacetyl; Try (Me), O-methyl-tyrosine. The MIA series of GHRH antagonists are derivatives of JMR-132, which was previously the most effective GHRH antagonist in oncologic tests. GHRH antagonists MIA-602, MIA-606, and MIA-690 were dissolved in 0.1% DMSO in 10% (vol/vol) aqueous propylene glycol solution (vehicle solution).
In Vitro Proliferation Assays. Western Blots. Cells or tumor samples were harvested in RIPA buffer. Samples were run in 10% SDS/PAGE gels and transferred onto nitrocellulose membranes (Bio-Rad). Membranes were blocked with 5% nonfat dry milk in TBS containing 0.1% Tween-20 (Sigma-Aldrich). Antibodies were diluted in 5% nonfat dry milk in TBS containing 0.1% Tween-20. GHRH-R antibody (detecting both full-length GHRH-R and variant SV1) was obtained from Abcam. Actin antibody and HPRT-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology. Membranes were developed using an enhanced chemiluminescence detection spray (Denville Scientific).
Total RNA Isolation and Reverse Transcription. Total RNA was isolated and DNase-treated from cultured 22Rv1, VCaP, and LNCaP human prostate cancer cells and from xenografted 22Rv1 and VCaP tumors using TRIzol (Invitrogen). Three tumor samples from each group were analyzed. The quality of RNA isolated was tested with a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). The OD 260 /OD 280 ratio was in the range of 1.8-2.1 for all samples. Finally, 2 μg of total RNA from each sample was reverse-transcribed into cDNA using the QuantiTect Reverse-Transcription Kit (Qiagen) in a final volume of 40 μL using a Veriti 96-well thermal cycler (Applied Biosystems).
Quantitative Real-Time RT-PCR. We evaluated the expression of mRNA for human GHRH-R, SV1, GHRH, and β-actin. Probes and primers for GHRH-R, β-actin, and sense-and antisense-specific primers for SV1 were described previously (28, 50) . The criteria for the design of human-specific primers were as described previously (55) . Quantitative real-time RT-PCR reactions were performed using the iQ5 Real-Time PCR Detection System (Bio-Rad). All thermal cycling conditions have been described previously (13) . In brief, samples were run in triplicate, with each well containing a final volume of 25 μL, including 2 μL of cDNA, 200 nM gene-specific primers, and 400 nM probes. iQ Supermix (Bio-Rad) was used in the PCR reactions for pGHRH-R, and β-actin and iQ SYBR-Green Supermix (Bio-Rad) were used in the reactions for SV1. The efficiencies of all primers (Invitrogen) and probes (Integrated DNA Technologies) were tested before the experiments and found to be efficient in the range of 95-105%. Normal human pituitary was used as a positive control, and human β-actin served as a housekeeping gene. Negative samples were run in each reaction, consisting of no-RNA in reverse transcriptase reactions and no-cDNA in PCR. Relative expression ratios were calculated using the method of Pfaffl (56) .
Xenograft Experiments. Experiments involving animals were performed following protocols reviewed and approved by the Institutional Animal Care and Use Committee. A total of 10 6 22Rv1 cells resuspended in PBS were mixed with equal volumes of Matrigel (BD Bioscience) and were injected s.c. into the flanks of 5-6 wk old nude mice (Harlan). Once a palpable tumor size was achieved, an average of 76 mm 3 , mice were randomized intro four groups and were treated with 5 μg of GHRH-R antagonist MIA-602, MIA-606, MIA-690, or vehicle daily for 3 wk. Tumors were measured weekly using calipers and the following formula: length × height × width × 0.5236. Mice were euthanized after 4 wk of treatment, and tumors were excised and flash-frozen for subsequent protein and RNA isolation. VCaP cells (10 6 ) were resuspended in PBS and mixed with equal volumes of Matrigel (BD Biosciences), then injected into the flanks of 5-to 6-wk-old SCID mice. On reaching an average tumor size of 248 mm 3 , mice were randomized into four groups. Mice were castrated or subjected to a sham surgery and then treated with 5 μg of GHRH-R antagonist MIA-602 or vehicle daily for 3 wk. Tumors were assessed and processed as described above.
Serum PSA Analysis. Blood samples obtained from mice bearing VCaP xenografts. Blood samples were allowed to clot and serum separated by centrifugation (10,000 × g for 10 min). Serum (25 μL) was mixed with 25 μL of PBS, and serum PSA was assessed with an ELISA-based assay (Biocheck) according to the manufacturer's protocol. Concentration of serum PSA was calculated using a standard curve.
Statistical Analysis. All statistical analyses were performed using SigmaStat 3.0 software (Systat Software). Results are expressed as mean ± SEM. Oneway ANOVA followed by the Bonferroni t test or a two-tailed Student t test was used where appropriate, and significance was accepted at P < 0.05.
